PRME Similar Chart Price Prediction
The price of PRME is predicted to go up -13.91%, based on the high correlation periods with CAKE. The similarity of these two price pattern on the periods is 93.12%.
PRME
CAKE
Down: -13.91%Similarity: 93.12%
PRME Revenue Forecast
PRME EPS Forecast
PRME FAQs
What is bull’s view on PRME?
What is bear's view on PRME?
What is PRME revenue forecast for next quarter？
What is PRME eps forecast for next quarter？
PRME Analyst's Forecast
Silvan Tuerkcan
JMP Securities
Buy
2024-12-10
Price Target
$10
Upside
+210.56%
JMP Securities initiated coverage of Prime Medicine with an Outperform rating and $10 price target. Prime is a clinical-stage biotechnology company focused on prime editing-based therapies, which enable editing, correcting, inserting, and deleting DNA sequences for an unprecedented range of tissues and genes, the analyst tells investors in a research note. The firm says this unlocks several indications not covered by other editing technologies. JMP views the current share price as supported by the Wilson's disease program alone, leaving "much of the pipeline value as upside."
